Loading organizations...

§ Private Profile · Newton, MA, USA
Biotechnology company developing targeted therapies for oncology and inflammatory diseases using its AURION AI platform.
Auron Therapeutics is a Newton, Massachusetts-based biotechnology company that develops targeted cancer and inflammatory disease treatments by utilizing a proprietary machine learning platform to analyze cellular plasticity. The organization leverages its AURION artificial intelligence system and a database of single-cell genomic data to map healthy cell states against diseased ones, identifying novel drug targets that can halt tumor growth or revert cancerous cells to a normal state. To support its proprietary drug discovery and development pipeline focused on addressing the root causes of disease, the privately held firm secured $48 million in Series A financing in July 2022. This critical funding round was led by the venture capital firm DCVC Bio, with additional strategic investments from Mubadala Capital and the pharmaceutical corporation Eli Lilly and Company. Auron Therapeutics was founded in 2018 by Katharine Yen.
Auron Therapeutics has raised $87.8M across 3 funding rounds.
Auron Therapeutics has raised $87.8M in total across 3 funding rounds.
# Auron Therapeutics: A Biotech Pioneer, Not a Technology Company
Auron Therapeutics is a biopharmaceutical company, not a technology company. While it employs advanced computational tools, its primary mission is developing cancer therapeutics through a novel approach called differentiation therapy.
Auron Therapeutics develops small-molecule drugs targeting cell-state plasticity to treat solid tumors and hematological malignancies.[1] Rather than killing cancer cells—the traditional oncology paradigm—Auron aims to transform cancer cells into normal, healthy tissue through differentiation therapy.[2] The company serves cancer patients by addressing a fundamental problem: dysregulated cellular differentiation that drives tumor progression.
Founded in 2018 and based in Newton, Massachusetts, Auron operates as a platform-powered, product-driven company.[1][5] Its lead program, AUTX-703, targets KAT2A and KAT2B in refractory myelodysplastic syndrome and is currently in Phase 1 clinical trials.[5] The company has assembled a pipeline spanning multiple cancer types, including small cell lung cancer (SCLC) and acute myeloid leukemia (AML), with three additional undisclosed programs in research and development.[1]
Auron operates at the intersection of precision oncology and computational biology—two accelerating trends in drug development. The company's focus on cell-state plasticity addresses a growing recognition that cancer heterogeneity and cellular plasticity are fundamental drivers of treatment resistance and disease progression. By leveraging single-cell genomics and AI to decode these mechanisms, Auron represents a shift toward mechanism-driven drug discovery rather than target-agnostic screening.
The timing is favorable: advances in single-cell sequencing, machine learning infrastructure, and a deeper understanding of cancer biology have made this approach feasible. Auron's success could validate differentiation therapy as a viable complement to immunotherapy and targeted approaches, potentially influencing how the broader oncology field conceptualizes cancer treatment.
Auron stands at an inflection point. With AUTX-703 in Phase 1 trials and a pipeline spanning multiple indications, the company's near-term trajectory depends on clinical validation of its differentiation therapy hypothesis. If early-stage data supports efficacy and tolerability, Auron could establish a new therapeutic category and attract significant capital.
The broader question is whether cell-state plasticity targeting can deliver durable responses in hard-to-treat cancers. Success here would vindicate the company's computational platform and potentially open new applications beyond oncology—the company is already exploring inflammatory diseases like rheumatoid arthritis.[5] As precision medicine and AI-driven drug discovery mature, companies like Auron that combine novel biology with computational rigor will likely define the next generation of biotech innovation.
Auron Therapeutics has raised $87.8M in total across 3 funding rounds.
Auron Therapeutics's investors include Apollo Health Ventures, Cofounders Capital, Eric Shiozaki, Polaris Partners, Agent Capital, Bain Capital Life Sciences, DCVC (Data Collective), Franklin Berger, Arkin Bio Ventures, BrightEdge, Casdin Capital, Eli Lilly and Company.
Auron Therapeutics has raised $87.8M across 3 funding rounds. Most recently, it raised $27.0M Series B in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $27M Series B | — | Apollo Health Ventures, Cofounders Capital, Eric Shiozaki, Polaris Partners | Announced |
| Jul 1, 2022 | $48M Series A | DCVC BIO | Agent Capital, Apollo Health Ventures, Bain Capital Life Sciences, Cofounders Capital, Eric Shiozaki, Dcvc (data Collective), Polaris Partners, Franklin Berger, Arkin BIO Ventures, BrightEdge, Casdin Capital, ELI Lilly And Company, Rami Hannoush, Ph.d., Alexandra Cantley, Qiming Venture Partners USA | Announced |
| Jan 27, 2021 | $12.8M Seed | Alon Lazarus IN Remembrance, Isaac Ciechanover, Anna French, Dphil | Franklin Berger, BrightEdge, Casdin Capital, Brad Robling | Announced |